Incyte Corp (MIL:1INCY)
€ 66.84 0 (0%) Market Cap: 13.69 Bil Enterprise Value: 12.09 Bil PE Ratio: 541.07 PB Ratio: 4.61 GF Score: 70/100

Incyte Corp Corporate Call - Data from Phase 3 TRuE-AD Trials of Ruxolitinib Cream in Atopic Dermatitis Transcript

Apr 06, 2020 / 12:00PM GMT
Operator

Greetings, and welcome to the Ruxolitinib Cream Phase III Data in Atopic Dermatitis webcast. (Operator Instructions) As a reminder, this conference is being recorded.

It's now my pleasure to introduce Head of Investor Relations, Mike Booth. Please go ahead, Mike.

Michael Booth
Incyte Corporation - Divisional VP of IR & Corporate Social Responsibility

Thank you, Kevin. Good morning, and welcome to our conference call and webcast to discuss atopic dermatitis, the disease, the medical need and the Phase III ruxolitinib cream data presented yesterday at the Revolutionizing Atopic Dermatitis â Virtual Symposium. The slides used in today's webcast and those presented yesterday are available for download on the Investors section of incyte.com.

I'm joined on the call today by Hervé and by Jim Lee, our Head of Inflammation and Autoimmunity Development. And we're also delighted to welcome Dr. Larry Eichenfield from the University of San Diego. Dr. Eichenfield is a world-renowned expert in atopic dermatitis. He is a -- he is Professor of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot